Engineered immune cells take on brain cancer in early trial

This early study tested the safety of a treatment called tisagenlecleucel in 13 people with primary central nervous system lymphoma, a rare type of brain cancer. The treatment uses specially engineered immune cells (CAR T cells) to target and attack cancer cells. The main goal was to check for side effects, with a secondary focus on whether the treatment could shrink tumors.